SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nutrition

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: nigel bates10/11/2006 10:42:57 AM
   of 577
 
Omega-3 fatty acids may slow very early Alzheimer's
1 hour, 15 minutes ago
NEW YORK (Reuters Health) - Dietary supplementation with omega-3 fatty acids for 6 months appears to be of little benefit in patients with mild to moderate Alzheimer's disease (AD), according to results of a study conducted in Sweden.

However, a second look at the data suggests that omego-3 fatty acids may protect cognitive function in patients with very mild, early stage AD.

Studies have shown that a diet rich in omega-3 fatty acids, as found in fish oil, reduces the risk of AD. Furthermore, animal studies have shown that the two predominant omega-3 fatty acids in fish oil, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), preserve cognitive function.

To evaluate the effect of DHA/EPA on patients already diagnosed with AD, investigators led by Dr. Jan Palmblad, from Karolinska University Hospital Huddinge in Stockholm, randomly recruited 174 patients with mild to moderate AD.

Eighty-nine patients were assigned 430 mg DHA plus 150 mg EPA, administered four times daily, and 85 were assigned placebo for 6 months during blinded portion of the trial. For the next 6 months, both groups were given the DHA/EPA supplement.

As demonstrated by Mini-Mental State Examination (MMSE) scores and the modified cognitive portion of the Alzheimer Disease Assessment Scale (ADAS-COG), the two treatment groups did not differ significantly at 6 months or at 12 months.

But when Palmblad's group conducted a post-hoc analysis of the 32 patients with very mild AD at baseline, those first treated with placebo exhibited a significant decline in MMSE score at 6 months, whereas scores remained stable in those treated with DHA/EPA.

The researchers say their results, coupled with other studies, "support the idea that omega-3 fatty acids have a role in primary prevention of AD but not in treatment of manifest disease," when the "neuropathologic involvement is too advanced to be substantially attenuated by anti-inflammatory treatment."

SOURCE: Archives of Neurology October 2006.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext